Somatuline Depot
Somatuline Depot (lanreotide) is a long-acting somatostatin analog. It works by reducing the levels of certain hormones in the body, such as growth hormone (GH) and insulin-like growth factor-1 (IGF-1), and by suppressing the growth of gastroenteropancreatic neuroendocrine tumors.
Dosage by Body Weight
Administered only by a healthcare professional via deep subcutaneous injection. For acromegaly, the recommended starting dose is 90 mg every 4 weeks for 3 months, then adjusted based on hormone levels and symptoms. For GEP-NETs and carcinoid syndrome, the recommended dose is 120 mg every 4 weeks.
- Body Weight
- Below 5 kg
- Dose
- Not indicated
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness in pediatric patients have not been established.
- Body Weight
- 5-7 kg
- Dose
- Not indicated
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness in pediatric patients have not been established.
- Body Weight
- 8-10 kg
- Dose
- Not indicated
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness in pediatric patients have not been established.
- Body Weight
- 11-15 kg
- Dose
- Not indicated
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness in pediatric patients have not been established.
- Body Weight
- 16-20 kg
- Dose
- Not indicated
- Frequency
- N/A
- Tracking Notes
- Safety and effectiveness in pediatric patients have not been established.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Not indicated | N/A | Safety and effectiveness in pediatric patients have not been established. |
| 5-7 kg | Not indicated | N/A | Safety and effectiveness in pediatric patients have not been established. |
| 8-10 kg | Not indicated | N/A | Safety and effectiveness in pediatric patients have not been established. |
| 11-15 kg | Not indicated | N/A | Safety and effectiveness in pediatric patients have not been established. |
| 16-20 kg | Not indicated | N/A | Safety and effectiveness in pediatric patients have not been established. |
Formulation
Purpose
Used for the long-term treatment of acromegaly in patients who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy. It is also indicated for the treatment of adults with unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEPs-NETs), and for the treatment of adults with carcinoid syndrome to reduce the frequency of rescue somatostatin analog use.
Generic Name
Lanreotide acetateScheduled Drug
Yes. This medicine should be supplied or used only according to applicable prescription and regulatory requirements.